Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
STING-AGONIST COMPOUND
Document Type and Number:
WIPO Patent Application WO/2020/075790
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a pharmaceutical product containing, as an active ingredient, a compound having agonistic activity to STING. As a result of extensive investigations, the inventors of the present invention have discovered, as substances capable of solving the problem, compounds represented by general formula (I-1) [all of the symbols in the formula are as described in the description] and having agonistic activity to STING, thereby arriving at the present invention. The compounds represented by general formula (I-1) according to the present invention have agonistic activity to STING, and can thus be used as active ingredients of agents for treating, suppressing the progress of, and/or suppressing the recurrence of cancer or infectious diseases.

More Like This:
WO/2014/194519IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING PHARMACOKINETICS OF DRUG
JPH08109183BICYCLIC OXAZOLE AND THIAZOLE-SUBSTITUTED ETHER
WO/2002/094225GRANULAR PREPARATIONS OF GABOXADOL
Inventors:
HANADA RYOSUKE (JP)
KOKUBO MASAYA (JP)
KURONO MASAKUNI (JP)
KOUDA KENICHI (JP)
HAGIYA HIROSHI (JP)
Application Number:
PCT/JP2019/039941
Publication Date:
April 16, 2020
Filing Date:
October 10, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ONO PHARMACEUTICAL CO (JP)
International Classes:
C07D498/04; A61K31/437; A61K45/00; A61P31/00; A61P35/00; A61P35/02; C07D513/04
Domestic Patent References:
WO2017093933A12017-06-08
WO2017186711A12017-11-02
WO2017106740A12017-06-22
WO2017175156A12017-10-12
WO2018067423A12018-04-12
WO2006007448A22006-01-19
WO2014151634A12014-09-25
WO2016039749A12016-03-17
WO2016057624A12016-04-14
WO2016077518A12016-05-19
WO2016100285A12016-06-23
WO2016100608A12016-06-23
WO2016126646A12016-08-11
WO2016149351A12016-09-22
WO2017151830A12017-09-08
WO2017176608A12017-10-12
WO2015034820A12015-03-12
WO2015160641A22015-10-22
WO2017066227A12017-04-20
WO2017070089A12017-04-27
WO2017087777A12017-05-26
WO2017106634A12017-06-22
WO2017112730A12017-06-29
WO2017192961A12017-11-09
WO2017205464A12017-11-30
WO2017202273A12017-11-30
WO2017202274A12017-11-30
WO2017202275A12017-11-30
WO2017202276A12017-11-30
WO2017118762A12017-07-13
WO2006121168A12006-11-16
WO2008156712A12008-12-24
WO2007005874A22007-01-11
WO2001014424A22001-03-01
Foreign References:
JP2002069061A2002-03-08
JP2018516903A2018-06-28
US20170050967A12017-02-23
US20170146519A12017-05-25
US2868691A1959-01-13
US3095355A1963-06-25
Other References:
DEVAUX L., CURR. OPI. MICROBIOL., vol. 41, 2018, pages 21 - 28
CORRALES L., CELL REP, vol. 11, no. 7, 2015, pages 1018 - 1030
SALI T.M., PLOS PATLIOG., vol. 11, no. 12, pages el005324
HIROKAWA SHOTEN: "Development of Pharmaceuticals", MOLECULAR DESIGN, vol. 7, 1990, pages 163 - 198
"Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS INC
ONCOTARGET, vol. 8, no. 42, 22 September 2017 (2017-09-22), pages 72167 - 72181
ANGEW. CHEM. HIT. ED., vol. 54, 2015, pages 11760 - 11764
CAS , no. 1326283-60-6
See also references of EP 3868764A4
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: TRANSPARENT SEALING MEMBER AND OPTICAL COMPONENT

Next Patent: ARC WELDING CONTROL METHOD